# Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-interactions-incretin-mimetics-glp-1-receptor-agonists-evidence/ > **Published:** 2026-10-16T12:40:45-04:00 | **Last Modified / Clinically Audited:** 2026-10-16T23:17:12-04:00 > **Clinical Summary:** Pharmacology & Safety Series Clinically Audited: October 2026 Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review Author & Reviewer: Benjamin Caplan, MD • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with incretin mimetics & glp-1 receptor agonists primarily through Non-enzymatic pharmacokinetic interaction driven […] --- Pharmacology & Safety Series Clinically Audited: October 2026 Table of Contents - [Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review](#Cannabinoids_038_Incretin_Mimetics_038_GLP-1_Receptor_Agonists_Evidence_Pharmacokinetics_038_Safety_Review)[1. The Primary Pharmacokinetic Mechanism](#1_The_Primary_Pharmacokinetic_Mechanism)[Incretin-Based Polypharmacology and the Redefinition of Cardiometabolic Medicine](#Incretin-Based_Polypharmacology_and_the_Redefinition_of_Cardiometabolic_Medicine) - [Managing Interactions Without Therapeutic Compromise](#Managing_Interactions_Without_Therapeutic_Compromise)[Does cannabis or CBD interact with Incretin Mimetics & GLP-1 Receptor Agonists?](#Does_cannabis_or_CBD_interact_with_Incretin_Mimetics_038_GLP-1_Receptor_Agonists) - [What monitoring or laboratory surveillance is required when taking cannabinoids alongside Incretin Mimetics & GLP-1 Receptor Agonists?](#What_monitoring_or_laboratory_surveillance_is_required_when_taking_cannabinoids_alongside_Incretin_Mimetics_038_GLP-1_Receptor_Agonists) - [Related](#Related) # Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review **Author & Reviewer:** [Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with incretin mimetics & glp-1 receptor agonists primarily through Non-enzymatic pharmacokinetic interaction driven by delayed gastric emptying, which can alter oral cannabinoid absorption timelines (delaying Tmax and flattening Cmax peaks). Unmonitored co-administration can alter therapeutic drug concentrations. Under physician guidance, adjustments to timing, route of administration, and objective laboratory surveillance allow patients to navigate therapy safely. ## 1. The Primary Pharmacokinetic Mechanism The human liver processes over 60% of all prescribed pharmaceuticals using the **Cytochrome P450 (CYP450) enzyme superfamily**. Cannabinoids—most notably cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)—are both substrates and competitive inhibitors of specific CYP isoenzymes. Enzyme Pathway Dynamics **Mechanism:** Non-enzymatic pharmacokinetic interaction driven by delayed gastric emptying, which can alter oral cannabinoid absorption timelines (delaying Tmax and flattening Cmax peaks). **Medications Impacted:** Semaglutide (Ozempic, Wegovy), Tirzepatide (Mounjaro, Zepbound). Featured Peer-Reviewed Investigation Journal of Pharmaceutical and Biopharmaceutical Research (2026) ### Incretin-Based Polypharmacology and the Redefinition of Cardiometabolic Medicine **Lead Investigators:** Sujit B. Kanoia, Anuansh Tiwari, Syed Wajahat Abbas Rizvi, Anuanshika Tiwari | **Identifier:** Clinical Citation **Study Findings & Abstract:** Within little more than a decade, agonists of the glucagon-like peptide-1 (GLP-1) receptor have moved from incremental glucose-lowering agents to the most consequential drug class in cardiometabolic medicine. The defining advance has been less a single molecule than a design strategy—rational polypharmacology—in which one peptide, or a fixed co-formulation, engages two or three nutrient-sensing receptors. In this narrative review, built from a documented search of the primary literature and graded by level of evidence, we trace the resulting efficacy ladder from single GLP-1 agonism (≈15% mean weight loss with semaglutide) through dual GLP-1/GIP agonism (tirzepatide, ≈21%) to triple GLP-1/GIP/glucagon agonism (retatrutide, 24% in phase 2, with provisional phase 3 topline results in the high-20% range). We argue that the class’s significance lies less in weight than in convergent benefits across cardiovascular, renal, respiratory and hepatic disease; synthesize the pivotal outcome trials (SELECT, FLOW, SURPASS-CVOT, SURMOUNT-OSA, SUMMIT, ESSENCE); quantify the principal safety signals in absolute terms; and confront the unresolved problems of durability, tolerability, lean-mass loss, special populations, cost and equitable access. Negative results—most notably the failure of oral semaglutide to slow early Alzheimer’s disease in EVOKE and EVOKE+—are given equal weight. [Access PubMed / DOI Reference Record →](https://doi.org/10.25082/jpbr.2026.01.004) Dr. Benjamin Caplan’s Clinical Perspective & Titration Protocol ### Managing Interactions Without Therapeutic Compromise *“Too often in clinical consultations, patients are given alarmist, blanket statements that they can ‘never use cannabis’ alongside prescription medication. In truth, pharmacology is a science of doses, affinities, and kinetics. When co-managing patients on incretin mimetics & glp-1 receptor agonists, the goal is never to guess. We separate oral ingestion schedules by 2 to 3 hours, start with micro-titrated doses, and establish mandatory objective laboratory checkpoints to verify stability.”* **Mandatory Clinical Monitoring:** Symptom logs tracking gastrointestinal motility, post-ingestion latency, nausea scores, and blood glucose stability. **Clinical Authority Context:** Dr. Benjamin Caplan, MD has overseen more than 350,000 patient evaluations across his career (including supervising 250,000+ patients as former Chief Medical Officer of Canna Care Docs). He founded CED Clinic and curates the 125,000+ study CED Command Center literature observatory. Frequently Asked Clinical Questions • Direct Answers #### Does cannabis or CBD interact with Incretin Mimetics & GLP-1 Receptor Agonists? Cannabinoids interact with incretin mimetics & glp-1 receptor agonists primarily through Non-enzymatic pharmacokinetic interaction driven by delayed gastric emptying, which can alter oral cannabinoid absorption timelines (delaying Tmax and flattening Cmax peaks). Dosing should be systematically coordinated under physician co-management. #### What monitoring or laboratory surveillance is required when taking cannabinoids alongside Incretin Mimetics & GLP-1 Receptor Agonists? Symptom logs tracking gastrointestinal motility, post-ingestion latency, nausea scores, and blood glucose stability. Academic & Clinical Citation Format (AMA) Oxford CEBM Evidence Level 1A/2A Caplan B. Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists: Evidence, Pharmacokinetics & Safety Review. *CED Clinic Medication Safety & Pharmacology Series*. Published October 2026. https://cedclinic.com/cannabinoid-interactions-incretin-mimetics-glp-1-receptor-agonists-evidence/ [View Dr. Caplan’s Research & Bio →](https://cedclinic.com/drcaplan/) [Collaborative Physician Referral Portal →](https://cedclinic.com/physician-referral/) [Complex Medication Advisory →](https://cedclinic.com/advisor/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).